Sarah Hammer

Sarah Hammer is a medical oncologist investigating immunotherapy strategies for adrenocortical carcinoma, including pembrolizumab and nivolumab monotherapy and combination regimens. Her research has focused on understanding why ACC has low immunotherapy response rates despite some cases with high TMB, and has identified hypercortisolism and adrenal immune suppression as key resistance mechanisms. She has contributed to correlative studies on ACC tumor microenvironment in patients enrolled on checkpoint inhibitor trials and investigates novel combinations to overcome ACC immune exclusion.